Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL466085 | 1.00 | CYP2D6 (0.32) | CYP2D6CTDSP1ARG1ALDH1A1TDP1 | |
| SCHEMBL7213243 | 1.00 | CYP2D6 (0.32) | CYP2D6CTDSP1ARG1ALDH1A1TDP1 | |
| SCHEMBL466084 | 1.00 | CYP2D6 (0.32) | CYP2D6CTDSP1ARG1ALDH1A1TDP1 | |
| SCHEMBL14199658 | 1.00 | CYP2D6 (0.32) | CYP2D6CTDSP1ARG1ALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL907395 | 0.98 | CYP2D6 (0.31) | CYP2D6CTDSP1ARG1 | |
| Hydrochloric Acid SCHEMBL907394 | 0.98 | CYP2D6 (0.31) | CYP2D6CTDSP1ARG1 | |
| SCHEMBL19508493 | 0.94 | CYP1A2 (0.31) | CYP2D6CTDSP1 | |
| SCHEMBL556230 | 0.84 | ARG1 (0.32) | ARG1ALDH1A1TDP1 | |
| SCHEMBL466148 | 0.83 | ARG1 (0.36) | CYP2D6CTDSP1ARG1ALDH1A1 | |
| SCHEMBL466147 | 0.83 | ARG1 (0.36) | CYP2D6CTDSP1ARG1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2277850-A1 | 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists | Merz Pharma GmbH & Co. KGaA (DE) | 2011-01-26 | — | — | EP | claimed |
| EP-2260839-A2 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors | Merz Pharma GmbH & Co. KGaA (DE) | 2010-12-15 | — | — | EP | claimed |
| US-20100298442-A1 | 1-Amino-alkyl-cyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-11-25 | — | — | US | claimed |
| EP-1682109-B1 | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC AS PEPTIDES IN AMYLOIDOPATHIES | MERZ PHARMA GMBH & CO KGAA (DE) | 2008-10-15 | — | — | EP | claimed |
| US-20070105961-A1 | 1-Amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-05-10 | — | — | US | claimed |
| US-20060205822-A1 | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect | FOREST LABORATORIES, INC. (US) | 2006-09-14 | — | — | US | claimed |
| EP-1556019-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | Merz Pharma GmbH & Co. KGaA (DE) | 2005-07-27 | — | — | EP | claimed |
| US-20050113458-A1 | delivering to said cell an 1-aminocyclohexane derivative; for decreasing the level of at least one amyloid peptide produced by a mammalian cell that expresses amyloid precursor protein | FOREST LABORATORIES, INC. (US) | 2005-05-26 | — | — | US | claimed |
| EP-1318800-B1 | 1-AMINO-ALKYLCYCLOHEXANES AS TRYPANOCIDAL AGENTS | MERZ PHARMA GMBH & CO KGAA (DE) | 2005-01-26 | — | — | EP | claimed |
| WO-2004037234-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | WO | claimed |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | US | claimed |
| US-20210169864-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO KGAA (DE) | 2021-06-10 | — | — | US | disclosed |
| US-20170319611-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | UNIV VANDERBILT (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170027885-A1 | 1-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF COCHLEAR TINNITUS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2017-02-02 | — | — | US | disclosed |
| US-9498450-B2 | 1-aminocyclohexane derivatives for the treatment of cochlear tinnitus | MERZ PHARMA GMBH & CO. KGAA (DE) | 2016-11-22 | — | — | US | disclosed |
| EP-1318800-B1 | 1-AMINO-ALKYLCYCLOHEXANES AS TRYPANOCIDAL AGENTS | MERZ PHARMA GMBH & CO KGAA (DE) | 2005-01-26 | — | — | EP | disclosed |
| US-20050014743-A1 | Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders | FOREST LABORATORIES, INC. (US) | 2005-01-20 | — | — | US | disclosed |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | US | disclosed |
| EP-1303477-A2 | 1-AMINO-ALKYLCYCLOHEXANES AS 5-HT3- AND NEURONAL NICOTINICRECEPTOR ANTAGONISTS | MERZ + CO. GmbH & Co. (DE) | 2003-04-23 | — | — | EP | disclosed |
| WO-2001098253-A2 | 1-AMINO-ALKYLCYCLOHEXANES AS 5-HT3 AND NEURONAL NICOTINICRECEPTOR ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210169864-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | ACHE, PSEN1, BCHE | CYP2D6 778/4885CTDSP1 2769/4885ARG1 2351/4885 |
| US-20070105961-A1 | 1-Amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists | HTR3A, CHRNA3, HTR3B | CYP2D6 1771/4885CTDSP1 2853/4885ARG1 3913/4885 |
| US-20170027885-A1 | 1-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF COCHLEAR TINNITUS | OTC, CNR2, CNR1 | CYP2D6 3424/4885CTDSP1 4385/4885ARG1 2382/4885 |
| US-20050113458-A1 | delivering to said cell an 1-aminocyclohexane derivative; for decreasing the level of at least one amyloid peptide produced by a mammalian cell that expresses amyloid precursor protein | APP, BACE1, PSEN1 | CYP2D6 4116/4885CTDSP1 3772/4885ARG1 1754/4885 |
| US-20170319611-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | PLD1, PLD2, PIK3CD | CYP2D6 3928/4885CTDSP1 483/4885ARG1 3618/4885 |
| US-20050014743-A1 | Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders | GRIN2A, GRIN2B, GRIN3B | CYP2D6 1862/4885CTDSP1 3569/4885ARG1 3568/4885 |
| US-20100298442-A1 | 1-Amino-alkyl-cyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists | HTR3A, CHRNA3, HTR3B | CYP2D6 1681/4885CTDSP1 2874/4885ARG1 3665/4885 |
| US-20060205822-A1 | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect | NMBR, NMUR1, CNR1 | CYP2D6 2649/4885CTDSP1 4320/4885ARG1 3507/4885 |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | ACHE, BACE1, CHRNA5 | CYP2D6 1027/4885CTDSP1 3856/4885ARG1 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.